Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01941758 · ClinicalTrials.gov registry record · Phase 1
High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01941758 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 28 participants.
The verdict
NCT01941758, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This pilot clinical trial studies high-dose trivalent influenza vaccine in inducing immune response patients with central nervous system tumors. Studying samples of blood in the laboratory from patients receiving trivalent influenza vaccine may help doctors learn more about the effects of trivalent influenza vaccine on cells. It may also help doctors understand how well patients respond to treatment.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL trivalent influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01941758
The ClinicalTrials.gov registry entry for NCT01941758 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01941758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01941758 about?
NCT01941758 is a clinical study titled "High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors". This pilot clinical trial studies high-dose trivalent influenza vaccine in inducing immune response patients with central nervous system tumors. Studying samples of blood in the laboratory from patients receiving trivalent influenza vaccine may help doctors learn more about the effects of trivalent ...
What is the current status of trial NCT01941758?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2013-11. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01941758?
The interventions under investigation include: laboratory biomarker analysis (OTHER), trivalent influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01941758?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.